Regence found that implementing strategies to increase its biosimilar adoption rate reduced spending on specialty drugs by $37 million annually. The organization is the latest example of how biosimilar use has contributed to significant savings.
Regence health plans announced that achieving a 95% biosimilar adoption rate reduced spending on specialty drugs by $37 million annually. The organization is the latest example of how biosimilar use has contributed to significant savings.
“Biosimilar adoption involves collaboration between multiple segments of the health care system, including members, providers, payers and manufacturers….Accelerating biosimilar use will drive meaningful cost savings and health care sustainability, while maintaining quality of care for some of the most complex diseases members face,” commented David Robertson, vice president of pharmacy services at Regence.
The average annual cost of biologics, especially specialty drugs, can cost plans tens of thousands of dollars per member. However, specialty medicines account for less than 2% of insurance claims within Regence plans despite accounting for over 55% of the organization’s total annual drug spend. Biosimilars typically cost about 15% to 30% less than their reference biologics.
Regence’s plan to increase member adoption of biosimilars involved implementing a robust communication campaign and medical policies supporting member’s unique needs to minimize barriers to switching from reference products to biosimilars. Regence also developed educational material on biosimilars targeted at members and providers, highlighting the economic and clinical value that biosimilars can provide. Frequent and transparent communications with members and providers took place up to 6 months prior to patients switching to a biosimilar.
When choosing which biosimilars to prefer, Regence said that it evaluated manufacturer capacity to ensure treatments availability and minimal disruptions to supply chains. Prior authorization requirements were either removed or preapproved for preferred biosimilars to make it easier for patients to transition to a biosimilar.
Additionally, Regence gave notice about patient switches to infusion sites ahead of time to ensure that they would increase their supply of preferred biosimilars to meet higher demand.
Biosimilar Savings in Other Areas of Health Care
Recently, a report from the Association of Accessible Medicines found that utilization of biosimilars and generics have led to $373 billion in savings, of which $119 billion was from Medicare plans and $178 billion was from commercial plans. The report also estimated that the US health care system saved over $2.6 billion over the last 10 years because of the increased availability of biosimilars and generics.
Additionally, an article that examined a biosimilar adoption program found that Providence St Joseph Health, a large US nonprofit health system, created $26.9 million in cost savings and significantly increased biosimilar adoption rates.
According to a report published by the HHS Office of Inspector General, Medicare Part D planed missed out on between $84 million and $143 million in savings by failing to prioritize biosimilars over more expensive reference products.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
September 14th 2024A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.